



23/G
Linda
6/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Patrick BENOIT *et al.*

Title: AN ISOLATED PEPTIDE OR
POLYPEPTIDE OF THE
EXTRACELLULAR PORTION OF
THE HUMAN INTERFERON
RECEPTOR (IFN-R)

Appl. No.: 09/240,675

Filing Date: 02/02/1999

Examiner: S. Devi

Art Unit: 1645

<p>CERTIFICATE OF MAILING</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.</p> <p>_____</p> <p>(Printed Name)</p> <p>_____</p> <p>(Signature)</p> <p>_____</p> <p>(Date of Deposit)</p>

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 05 2002

OFFICE OF PETITIONS

Sir:

This communication is responsive to the Office Action dated February 1, 2002, concerning the above-referenced patent application. Applicants enclose with this paper a Petition for Extension of Time, plus payment, rendering the present response timely. Please amend the application as indicated below. In accordance with 37 C.F.R. § 1.121, the amended portions of the specification and claims are shown explicitly in the attached "Version with Markings to Show Changes Made."

In the Specification

On page 8, replace the 3 full paragraph spanning lines 15-21 with the one submitted herein.

Monoclonal antibodies of the invention can for example be prepared against the soluble form of the receptor. A hydrosoluble polypeptide corresponding to the soluble form of the INF-R is described on figure 2 of SEQ ID NO: 2. According to the present invention, a soluble form of the IFN-R

G'